在糖尿病临床实践中应用的血糖变异性的关键指数
Louis Monnier1, Fabrice Bonnet2, Claude Colette1
1Medical School of Montpellier, University of Montpellier, Montpellier, France.
Diabetes & metabolism
|October 26, 2023
概括
实现接近正常的糖尿病控制需要每天监测葡萄糖和HbA1c水平. 变化系数 (CV) 被提议作为评估葡萄糖变化和长期血糖控制的关键指标.
科学领域:
- 内分泌学 在内分泌学.
- 代谢疾病 代谢疾病
- 临床化学 临床化学
背景情况:
- 有效的糖尿病管理需要控制每天的葡萄糖波动和长期的HbA1c水平.
- 目前的葡萄糖变化的指标可能会受到平均葡萄糖度的影响.
- 确定短期和长期葡萄糖平衡的可靠指标至关重要.
研究的目的:
- 建立数学上合理的指标来评估糖尿病中的短期和长期葡萄糖变异性.
- 为了确定适当的值变化系数 (CV) 在葡萄糖和HbA1c测量.
主要方法:
- 使用变化系数 (CV = 标准偏差/平均值) 来分析葡萄糖和HbA1c数据.
- 评估CV值,以区分稳定与不稳定葡萄糖平衡.
- 评估CV值以尽量减少低血糖风险和预防不良临床结果.
主要成果:
- 36%的CV葡萄糖值被认为是稳定的葡萄糖平衡的适当值.
- 建议在接近正常的葡萄糖水平下降心血管葡萄糖值 (<27%) 以最大限度地降低低血糖的风险.
- 建议CVHbA1c值<5%作为预防与长期血糖控制相关的不良临床结果的相关值.
结论:
- 变化系数 (CV) 提供了一种可靠的方法来评估血糖变化,独立于平均葡萄糖水平.
- 提出了特定的CVglucose和CVHbA1c值,以指导接近正常的血糖控制并减少与糖尿病相关的并发症.
相关概念视频
Variability: Analysis
144
Measures of variability are statistical metrics that reveal the dispersion pattern within a dataset. They are pivotal in biostatistics, providing insights into the heterogeneity within health and biological data. Variability signifies the degree to which data points diverge from one another, helping researchers understand the potential range of values and associated uncertainty within the data.
The range is a simple measure of variability, indicating the difference between the highest and...
The range is a simple measure of variability, indicating the difference between the highest and...
144
Diabetes Mellitus: Type 2 and Gestational
2.5K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.5K
Oral Hypoglycemic Agents: Glinides
160
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
160
Diabetes Mellitus: Overview and Type I Subtype
2.7K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.7K
Oral Hypoglycemic Agents: Biguanides and Glitazones
212
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
212
Hypoglycemia and Glucagon
274
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
274


